PL Capital has upgraded Fortis Healthcare to a buy, projecting double‑digit earnings growth over the next few years. The brokerage’s report comes at a time when the Nifty Health Care Index is under pressure from broader market volatility, yet the firm believes the hospital chain’s fundamentals remain robust enough to deliver shareholder value. The recommendation follows a recent Delhi High Court order directing a probe into certain operational matters at Fortis.
PL Capital argues that the investigation is unlikely to affect the company’s revenue streams or its ability to meet debt obligations, noting that the chain’s extensive network of tertiary care hospitals continues to attract steady patient inflows. The firm also points to a strong balance sheet, improving occupancy rates, and a pipeline of new facilities as catalysts for future earnings. For retail investors tracking the Sensex and Nifty, Fortis Healthcare offers exposure to a sector that benefits from rising disposable incomes and an ageing population.
The health‑care segment has outperformed many traditional equities this fiscal year, and a positive analyst note could provide a short‑term boost to the stock, potentially narrowing the gap with sector peers. While the buy call adds a bullish note to the market, investors should weigh the ongoing legal scrutiny against the company’s growth trajectory. Diversifying across health‑care stocks and monitoring the probe’s developments can help manage risk while participating in the sector’s long‑term upside.